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Abstract
In order to develop novel antistaphylococcal strategies, understanding the determinants of carriage and how humans respond to
Staphylococcus aureus exposure is essential. Here, the primary S. aureus-speciﬁc humoral immune response and its association with nasal
colonization was studied in young children. Sera from 57 colonized or non-colonized children, serially collected at birth and at 6, 14
and 24 months, were analysed for IgG, IgA and IgM binding to 19 staphylococcal proteins, using ﬂow cytometry-based technology. The
antibody responses showed extensive inter-individual variability. On average, the levels of antistaphylococcal IgA and IgM increased from
birth until the age of 2 years (p <0.05), whereas the levels of IgG decreased (p <0.001). Placentally transferred maternal IgG did not
protect against colonization. In colonized children, IgG and IgA levels for a number of proteins were higher than in non-colonized chil-
dren. At both 14 and 24 months, the levels of IgG against chemotaxis inhibitory protein of S. aureus (at 24 months; median ﬂuores-
cence intensity, 4928 vs. 24, p <0.05), extracellular ﬁbrinogen-binding protein (987 vs. 604, p <0.05), and iron-responsive surface
determinant H (62 vs. 5, p <0.05) were signiﬁcantly higher in colonized children. The levels of IgA against CHIPS, IsdH and IsdA were
higher (p <0.05). Therefore, CHIPS, Efb, IsdA and IsdH seem to play a role in nasal colonization of young children.
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Introduction
Staphylococcus aureus efﬁciently colonizes human skin and,
most frequently, nasal mucosa [1]. Approximately 20–30% of
adults carry S. aureus persistently, and approximately 70–80%
of adults carry S. aureus never or intermittently [2,3]. S. aureus
is carried by 10–35% of children [4]. During the ﬁrst 2 months
of life, the prevalence of colonization is 40–50%. Then, the
prevalence rapidly decreases to approximately 20% by
6 months and to 10% by 14 months [5,6]. How nasal carriage
is established and maintained is still largely unknown [2,7],
although the involvement of bacterial components such as tei-
choic acid, catalase, hydroperoxide reductase, iron-responsive
surface determinant A (IsdA), S. aureus surface protein G and
clumping factor B (ClfB) has been demonstrated [8–13].
Carriage of S. aureus can result in serious endogenous
infections. Because of the increasing antibiotic resistance of
S. aureus, novel approaches concerning the prevention and
therapy of staphylococcal disease are urgently needed. In
order to develop such new strategies, understanding the
determinants of carriage and understanding how humans
respond to S. aureus exposure is essential. Here, we provide
insights into the antistaphylococcal humoral immune
response in young children. Studying their immune response
will allow us to distinguish the bacterial factors that are
expressed in vivo during early colonization. This may lead to
the discovery of novel determinants of colonization.
Materials and Methods
Study population
This project was performed with a subgroup of the Genera-
tion R Study, a population-based prospective cohort study of
pregnant women and their children from fetal life onwards
[14,15]. The infants were presented at the Generation R
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research centre at the ages of 1.5 months, 6 months,
14 months and 24 months. Research nurses obtained a nasal
swab for S. aureus isolation from each infant at each visit,
whenever possible. The methods of nasal sampling and iden-
tiﬁcation of S. aureus were as described previously [5].
Serum samples were collected from cord blood and through
venipuncture at 6 months, 14 months and 24 months when-
ever possible. Included in this study were 57 healthy chil-
dren, from each of whom three or four serial serum samples
were collected. Of the 177 samples that were obtained, 54
(31%) were cord blood samples; 32 samples (18%) were
obtained at 6 months, 46 (26%) at 14 months, and 45 (25%)
at 24 months. S. aureus colonization data were available at
1.5, 6, 14 and 24 months for 40 (70%), 49 (86%), 50 (88%)
and 48 (84%) children, respectively. Children were classiﬁed
as colonized if at least one of the nasal swab cultures was
positive for S. aureus. Children were classiﬁed as non-colo-
nized if all swab cultures were negative. Children with a cul-
ture moment missing at one time-point, and with the other
nasal swab cultures negative, were classiﬁed as non-colonized
as well.
None of the children suffered from apparent staphylococ-
cal infection. The Medical Ethics Committee of the Erasmus
MC, Rotterdam, The Netherlands, approved the study. Writ-
ten informed consent was obtained from the parents of all
participating children.
Antistaphylococcal antibodies
The levels of antistaphylococcal antibodies directed against
three important groups of S. aureus proteins, ‘microbial sur-
face components recognizing adhesive matrix molecules’
(MSCRAMMs), staphylococcal enterotoxins (SEs) and immu-
nomodulatory proteins, were determined. The proteins have
been described previously [16]. MSCRAMMs are generally
considered to be important for host colonization [12,17].
The recombinant MSCRAMMs clumping factor A (ClfA),
ClfB, S. aureus surface protein G, IsdA, iron-responsive sur-
face determinant H (IsdH), ﬁbronectin-binding protein A,
ﬁbronectin-binding protein B, serine–aspartate dipeptide
repeat protein D (SdrD) and serine–aspartate dipeptide
repeat protein E were used. SEs are superantigens, and
therefore potent pro-inﬂammatory agents [18]. The recom-
binant proteins SEA, SEB, SEI, SEM, SEO, SEQ and toxic
shock syndrome toxin-1 were used. Recombinant staphylo-
coccal complement inhibitor (SCIN), extracellular ﬁbrinogen-
binding protein (Efb) and chemotaxis inhibitory protein of
S. aureus (CHIPS) were also used. Efb and SCIN are comple-
ment inhibitors that lead to a reduction of bacterial phagocy-
tosis and killing by human neutrophils [19,20]. CHIPS impairs
the response of neutrophils and monocytes to formylated
peptides and complement factor C5a [21].
The levels of antigen-speciﬁc IgG, IgA and IgM were quan-
tiﬁed using the bead-based ﬂow cytometry technique (xMap;
Luminex Corporation, Austin, TX, USA). The methods used
were as described previously [16,22,23]. Tests were per-
formed as independent duplicates, and the median ﬂuores-
cence intensity (MFI) values, reﬂecting antibody levels
semiquantitatively, were averaged. In each experiment, con-
trol beads (no protein coupled) were included to determine
non-speciﬁc antibody binding. In cases of non-speciﬁc binding,
the median ﬂuorescence intensity values were subtracted
from the antigen-speciﬁc values. Human pooled serum was
used as a standard.
Statistical analysis
Statistical analyses were performed with SPSS version 15.0.
The Wilcoxon signed rank test was used to compare the
antistaphylococcal antibody levels between different age
groups. Mann–Whitney U-tests were used to compare differ-
ences in antibody levels between colonized and non-colo-
nized children. Binary logistic regression analysis was used to
determine the relationship between maternal IgG levels and
the dichotomous outcome colonization. A p-value £0.05 was
considered to be statistically signiﬁcant.
Results
Dynamics of the antistaphylococcal antibody response
The changes in antistaphylococcal IgG, IgA and IgM levels
during the ﬁrst 2 years of life were determined (Fig. 1; data
shown for toxic shock syndrome toxin-1, ClfB and Efb). The
levels of antigen-speciﬁc IgG, IgA and IgM showed extensive
inter-individual variability over time. For all S. aureus proteins
tested, the level of antigen-speciﬁc IgG in cord blood was
signiﬁcantly higher than the antistaphylococcal IgG level at
6 months (p <0.001). This was due to the presence of
maternal IgG at birth and catabolism of maternal IgG thereaf-
ter. In the time interval from 6 to 14 months, the levels of
IgG directed against CHIPS, SCIN and SEB decreased further
(p <0.05). As for the other proteins, no signiﬁcant change in
IgG levels was noted in this period.
Antistaphylococcal IgA and IgM levels in cord blood were
low, because maternal IgA and IgM are not transported
across the placenta. In the ﬁrst 2 years of life, IgA levels
remained low, which is a well-known fact [24,25]. However,
for both IgA and IgM, a signiﬁcant increase from birth up to
the age of 24 months was noted, for 18 of 19 S. aureus
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proteins in the case of IgA (p <0.05, with the exception of
anti-SCIN IgA) and for all proteins in the case of IgM
(p <0.01). It must be emphasized that not every infant devel-
oped an antigen-speciﬁc IgA or IgM response to each protein
in the ﬁrst 2 years of life. Within one individual, the level of
IgG, IgA or IgM directed against one protein was not corre-
lated with the level of IgG, IgA or IgM directed against
another protein.
Relationship between colonization and antistaphylococcal
antibody levels
It was determined whether maternal antistaphylococcal IgG
levels were predictive of the S. aureus colonization state of
the infant and whether the colonization state determines the
level of antistaphylococcal antibodies. Levels of S. aureus-spe-
ciﬁc IgG in cord blood were not predictive of the coloniza-
tion state at 1.5 and 6 months (p >0.05). This implies that
the large amounts of placentally transferred maternal IgG do
not protect children from becoming nasally colonized with S.
aureus.
For 45 of 46 (98%) children from whom serum samples
were obtained at 14 months, the colonization status was
known. For one child, the colonization status could not be
determined, because two nasal swab cultures were missing.
In the ﬁrst year of life, 24 (53%) children were colonized at
least once, and 21 children (47%) were not colonized. Colo-
nized children had signiﬁcantly higher levels of IgG directed
against CHIPS, Efb, ClfB, SdrD and IsdH than non-colonized
children (p <0.05; Fig. 2). In addition, their levels of IgA
directed against CHIPS, IsdA and IsdH were higher
(p <0.05). Incidentally, high levels of antibodies were detect-
able in non-colonized children, probably owing to exposure
to S. aureus that was not recorded during this study. For 42
of 45 (93%) children from whom serum samples were
obtained at 24 months, the colonization status was known.
In the ﬁrst 2 years of life, 24 (57%) children were colonized
at least once, and 18 (43%) were not colonized. Colonized
children had higher levels of IgG directed against CHIPS,
SCIN, Efb, IsdA, IsdH and SEB at 24 months than non-colo-
nized children (p <0.05; Fig. 2). Their levels of IgA directed
against CHIPS, IsdA and IsdH at 24 months were higher as
well (p <0.05). The levels of IgM did not differ signiﬁcantly
between colonized and non-colonized children (p >0.05).
Discussion
Understanding the determinants of carriage and how humans
respond to S. aureus exposure is important for the develop-
ment of novel antistaphylococcal measures. We show that,
FIG. 1. Levels of IgG, IgA and IgM directed against toxic shock syndrome toxin-1 (TSST-1), clumping factor B (ClfB) and extracellular ﬁbrino-
gen-binding protein (Efb) in 57 children at birth, 6 months, 14 months and 24 months. Antibody levels are reﬂected by median ﬂuorescence
intensity values. Each dot represents a serum sample. Median values are indicated by horizontal lines.
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despite extensive inter-individual variability, the levels of IgG
and IgA directed against a number of S. aureus proteins were
signiﬁcantly higher in colonized, more exposed children than
in non-colonized children. In both the ﬁrst and second years
of life, anti-CHIPS, anti-Efb and anti-IsdH IgG levels were
higher in colonized children. Furthermore, anti-CHIPS, anti-
IsdA and anti-IsdH IgA levels were higher. This indicates that
these proteins are expressed in vivo and that they might be
determinants for colonization in early childhood. A potential
role of IsdA in colonization was demonstrated in a previous
study [10].
Furthermore, we show that maternally derived IgG anti-
bodies speciﬁcally directed against a series of staphylococ-
cal antigens do not seem to protect the infant against
S. aureus nasal colonization in the ﬁrst months of life. Thus,
although it is known that maternal IgG can cross epithelial
barriers and reach signiﬁcant levels at the nasal mucosal
surface [26,27], these antibodies are not capable of pre-
venting nasal colonization. In healthy adults, the consider-
able levels of antistaphylococcal antibodies that are found
do not seem to protect against nasal colonization either.
Carriers have even higher levels of antibodies than non-
carriers [16]. These observations suggest that attempts to
prevent mucosal colonization by S. aureus through passive
immunization approaches are not likely to succeed.
Whether this also applies to active immunization remains
to be elucidated.
The present study was limited by the fact that the S. aur-
eus nasal swabs and serum samples were not available at all
times for all children. Furthermore, our study focused exclu-
sively on antibodies directed against S. aureus proteins. It
should be noted that cell wall components such as capsular
polysaccharides 5 and 8 [28], peptidoglycan [29] and teichoic
acid [8] are immunogenic as well.
FIG. 2. (a) Relationship between Staphylococccus aureus colonization in the ﬁrst year of life and levels of antistaphylococcal IgG, reﬂected by
median ﬂuorescence intensity (MFI) values, at 14 months. Each symbol represents a single child. Red triangles represent colonized children, and
blue diamonds represent non-colonized children. Median values are indicated by horizontal lines. (b) Relationship between S. aureus colonization
in the ﬁrst 2 years of life and the level of IgG at 24 months. CHIPS, chemotaxis inhibitory protein of S. aureus; SCIN, staphylococcal complement
inhibitor; Efb, extracellular ﬁbrinogen-binding protein; Clf, clumping factor; Sdr, serine–aspartate dipeptide repeat protein; Fnbp, ﬁbronectin-bind-
ing protein; Isd, iron-responsive surface determinant; SasG, S. aureus surface protein G; SE, staphylococcal enterotoxin; TSST-1, toxic shock syn-
drome toxin-1.
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In summary, in healthy children, the antistaphylococcal
IgG, IgA and IgM responses show extensive inter-individual
variability. On average, the levels of antistaphylococcal IgA
and IgM increase from birth until the age of 2 years, whereas
the levels of antistaphylococcal (maternal) IgG decrease. Plac-
entally transferred maternal IgG does not protect against
nasal colonization, whereas CHIPS, Efb, IsdA and IsdH are
expressed in vivo, and therefore seem to play a role in nasal
colonization of young children.
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